Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review
Danbin Wu
1
,
Yefei Chen
1
,
Yingxin Sun
1
,
Qing Gao
1
,
Huhu Li
1
,
Zhengfei Yang
1
,
Yangxue Wang
1
,
Xijuan Jiang
1
,
Bin Yu
2
Publication type: Journal Article
Publication date: 2019-10-23
scimago Q2
wos Q1
SJR: 1.270
CiteScore: 10.1
Impact factor: 5.0
ISSN: 03603997, 15732576
PubMed ID:
31646445
Immunology
Immunology and Allergy
Abstract
MCC950 has been proposed as a specific small molecule inhibitor that can selectively block NLRP3 inflammasome activation. However, the exact mechanism of its action is still ambiguous. Accumulating investigations imply that chloride efflux–dependent ASC speck oligomerization and potassium efflux–dependent activation of caspase-1 are the two relatively independent, but indispensable events for NLRP3 inflammasome activation. Previous studies suggested that influence of MCC950 on potassium efflux and its consequent events such as interaction between NEK7 and NLRP3 are limited. However, inhibiting chloride intracellular channel–dependent chloride efflux leads to a modification of inflammatory response, which is similar to the function of MCC950. Based on these findings, we shed new insights on the understanding of MCC950 that its function might correlate with chloride efflux, chloride intracellular channels, or other targets that act upstream of chloride efflux.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
|
|
|
Frontiers in Immunology
5 publications, 3.82%
|
|
|
International Immunopharmacology
5 publications, 3.82%
|
|
|
Biomedicine and Pharmacotherapy
4 publications, 3.05%
|
|
|
Frontiers in Cardiovascular Medicine
3 publications, 2.29%
|
|
|
Journal of Neuroinflammation
3 publications, 2.29%
|
|
|
Journal of Ethnopharmacology
3 publications, 2.29%
|
|
|
Journal of Inflammation Research
3 publications, 2.29%
|
|
|
Frontiers in Pharmacology
3 publications, 2.29%
|
|
|
Journal of Interferon and Cytokine Research
2 publications, 1.53%
|
|
|
Frontiers in Cell and Developmental Biology
2 publications, 1.53%
|
|
|
Molecular Immunology
2 publications, 1.53%
|
|
|
International Journal of Molecular Medicine
2 publications, 1.53%
|
|
|
Brain Research Bulletin
2 publications, 1.53%
|
|
|
Inflammopharmacology
2 publications, 1.53%
|
|
|
Respiratory Research
1 publication, 0.76%
|
|
|
Parasites and Vectors
1 publication, 0.76%
|
|
|
Viruses
1 publication, 0.76%
|
|
|
Frontiers in Physiology
1 publication, 0.76%
|
|
|
Frontiers in Chemistry
1 publication, 0.76%
|
|
|
Frontiers in Neuroscience
1 publication, 0.76%
|
|
|
Frontiers in Molecular Neuroscience
1 publication, 0.76%
|
|
|
Frontiers in Microbiology
1 publication, 0.76%
|
|
|
Acta Biochimica et Biophysica Sinica
1 publication, 0.76%
|
|
|
Cells
1 publication, 0.76%
|
|
|
Human Cell
1 publication, 0.76%
|
|
|
Inflammation
1 publication, 0.76%
|
|
|
Scientific Reports
1 publication, 0.76%
|
|
|
Journal of Cardiovascular Translational Research
1 publication, 0.76%
|
|
|
Veterinary Research Communications
1 publication, 0.76%
|
|
|
1
2
3
4
5
|
Publishers
|
5
10
15
20
25
30
35
40
45
|
|
|
Elsevier
42 publications, 32.06%
|
|
|
Springer Nature
24 publications, 18.32%
|
|
|
Frontiers Media S.A.
20 publications, 15.27%
|
|
|
Wiley
13 publications, 9.92%
|
|
|
MDPI
5 publications, 3.82%
|
|
|
Taylor & Francis
5 publications, 3.82%
|
|
|
Oxford University Press
4 publications, 3.05%
|
|
|
Mary Ann Liebert
3 publications, 2.29%
|
|
|
Spandidos Publications
2 publications, 1.53%
|
|
|
Hindawi Limited
2 publications, 1.53%
|
|
|
Royal Society of Chemistry (RSC)
2 publications, 1.53%
|
|
|
Bentham Science Publishers Ltd.
2 publications, 1.53%
|
|
|
SciELO
1 publication, 0.76%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.76%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 0.76%
|
|
|
Eco-Vector LLC
1 publication, 0.76%
|
|
|
Public Library of Science (PLoS)
1 publication, 0.76%
|
|
|
5
10
15
20
25
30
35
40
45
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
131
Total citations:
131
Citations from 2024:
52
(39.7%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Wu D. et al. Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review // Inflammation. 2019. Vol. 43. No. 1. pp. 17-23.
GOST all authors (up to 50)
Copy
Wu D., Chen Y., Sun Y., Gao Q., Li H., Yang Z., Wang Y., Jiang X., Yu B. Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review // Inflammation. 2019. Vol. 43. No. 1. pp. 17-23.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1007/s10753-019-01098-8
UR - https://doi.org/10.1007/s10753-019-01098-8
TI - Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review
T2 - Inflammation
AU - Wu, Danbin
AU - Chen, Yefei
AU - Sun, Yingxin
AU - Gao, Qing
AU - Li, Huhu
AU - Yang, Zhengfei
AU - Wang, Yangxue
AU - Jiang, Xijuan
AU - Yu, Bin
PY - 2019
DA - 2019/10/23
PB - Springer Nature
SP - 17-23
IS - 1
VL - 43
PMID - 31646445
SN - 0360-3997
SN - 1573-2576
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2019_Wu,
author = {Danbin Wu and Yefei Chen and Yingxin Sun and Qing Gao and Huhu Li and Zhengfei Yang and Yangxue Wang and Xijuan Jiang and Bin Yu},
title = {Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review},
journal = {Inflammation},
year = {2019},
volume = {43},
publisher = {Springer Nature},
month = {oct},
url = {https://doi.org/10.1007/s10753-019-01098-8},
number = {1},
pages = {17--23},
doi = {10.1007/s10753-019-01098-8}
}
Cite this
MLA
Copy
Wu, Danbin, et al. “Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review.” Inflammation, vol. 43, no. 1, Oct. 2019, pp. 17-23. https://doi.org/10.1007/s10753-019-01098-8.